|
Jun 27
|
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
|
|
Jun 26
|
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
|
|
Jan 23
|
HCW Biologics Insiders Placed Bullish Bets Worth US$2.50m
|
|
Aug 23
|
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
|
|
Nov 8
|
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
|
|
Apr 27
|
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
|